Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol>
ST3GAL IV conditional targeted mouseの受精卵にCAG-FLP plasmidをtransfectしたもので、ST34GAL targeted配列からneo遺伝子が除かれたマウス。
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers.<br>2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSIOR/DEVELOPER. At the same time, the RECIPENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate. <br>3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results.<br>4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not requie collaboration, the RECIPIENT agrees to cite the literatire(s) designated by the DEPOSITOR/DEVEVLOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered.<br>5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER. <br>6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity.
Mouse Models for Human Disease
Yoshio HIRABAYASHI
繁殖効率A
RBRC02287
true
2004年、平林義雄先生、RIKEN BSI
平林 義雄
ST34(#9 CAGflep)C57BL/6J, #9 CAGflep
ST34(#9 CAGflep)C57BL/6J, #9 CAGflep
独立行政法人理化学研究所
マウス ST3Gal IV(欠損), CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA), 酵母 FLP組換え酵素遺伝子, 酵母 FRT, P1 ファージ loxP
Cre/loxP system
FLP/frt system
D(6か月以上)
条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>1. 本件リソースの利用は、公表を前提とした学術研究に限る。<br>2. 利用者は事前に提供承諾書を得る。その際、利用者は、研究課題を寄託者に知らせ、その内容が共同研究に該当するかどうかの確認を得る。共同研究とするか否かは、寄託者側の判断による。<br>3. 共同研究に該当する場合には、別途、研究成果の取扱い等を定め、共同研究契約を結ぶこととする。<br>4. 共同研究に該当しない場合には、研究成果の公表にあたって寄託者の指定する文献を引用する。また、利用者が当該リソースを使用した研究成果に基づく特許の申請を行う場合は、寄託者と別途協議を行う。<br>5. 他の遺伝子改変マウスとの交配をする場合は、事前に寄託者の同意を得る。<br>6. 利用者から他の利用者への分与は禁止する。
C57BL/6-St3gal4<tm1.2Bsi> Tg(CAG-flp)1Bsi
C57BL/6-St3gal4<tm1.2Bsi> Tg(CAG-flp)1Bsi
D (more than 6 months)
RIKEN
Metabolism Research